Probiotec Limited

PBP

AU000000PBP7

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:40:37 15/05/2024 am IST			5-day change	1st Jan Change
2.9 ^AUD	-2.03%		+2.11%	0.00%

10/05	Foreign Investment Review Board Clears Probiotec Acquisition by Pyridam Farma	MT
27/02	Probiotec Limited Declares Interim Dividend, Payable on 15 March 2024	CI

Probiotec Limited Announces Earnings Guidance for the Full Year of 2021

June 09, 2021 at 04:00 am IST

Probiotec Limited announced earnings guidance for the full year of 2021. For the year, the company expects revenue to be $118 million to $122 million.

Latest news about Probiotec Limited

Foreign Investment Review Board Clears Probiotec Acquisition by Pyridam Farma	10/05	MT
Probiotec Limited Declares Interim Dividend, Payable on 15 March 2024	28/02	CI
Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
Probiotec Enters Scheme Implementation Bid With Indonesia-Listed Pyridam Farma	26/12	MT
Probiotec Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/23/25	CI
Probiotec Limited Declares Fully Franked Final Dividend for the Period of Six Months Ended June 30, 2023 , Payable on 8 September 2023	25/23/25	CI
Probiotec Limited Provides Sales Guidance for the Fiscal 2023	24/23/24	CI
Probiotec Limited Declares an Interim Dividend Payable on 17 March 2023	24/23/24	CI
Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
Probiotec to Consolidate NSW Operations with New Large-Scale Facility in Sydney	28/22/28	MT
Probiotec Limited Enters Agrees Terms with Major Australian Developer for Circa 30,000 Sqm Facility in Kemps Creek, NSW	28/22/28	CI
Probiotec Limited Announces Resignation of Paul Santoro as Non-Executive Director	17/22/17	CI
Probiotec Limited(ASX:PBP) dropped from S&P/ASX Emerging Companies Index	19/22/19	CI
Probiotec Limited Reports Earnings Results for the Full Year Ended June 30, 2022	24/22/24	CI
Probiotec Limited Announces Ordinary Fully Paid Dividend for the Twelve Months Ended June 30, 2022, Payable on September 15, 2022	24/22/24	CI
Probiotec Limited Provides Earnings Guidance for the Full Year 2022	25/22/25	CI
Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2021	25/22/25	CI
Probiotec Limited Announces Distribution for the Six Months Ended December 31, 2021, Payable on March 18, 2022	25/22/25	CI
Probiotec Limited Appoints Paul Santoro as Non-Executive Director	28/22/28	CI
Probiotec Limited Reports Earnings Results for the Full Year Ended June 30, 2021	25/21/25	CI
Probiotec Limited Declares Final Dividend for the Financial Year Ended 30 June 2021, Payable on 8 October 2021	25/21/25	CI
Probiotec : Acquires H&H Packaging for Up to $2.9 Million	02/21/02	MT
Probiotec Limited (ASX: PBP) completed the acquisition of assets and business of H&H Packaging.	01/21/01	CI
Probiotec : To Acquire H&H Packaging for up to $3 Million; Shares Up 5%	28/21/28	MT
Probiotec Limited Appoints Simon Gray as an Independent Non-Executive Director, Effective 1 July 2021	28/21/28	CI

Probiotec Limited is an Australia-based manufacturer, packer and distributor of a range of prescription and over the counter (OTC) pharmaceuticals, complementary medicines, consumer health products, and fast-moving consumer goods (FMCG). The Company owns approximately six manufacturing facilities in Australia and distributes its products both domestically and internationally. It offers full-service contract manufacturing and packing. The Company manufactures products on behalf of a range of clients, including international pharmaceutical companies. The Company services blue-chip manufacturers, multinational FMCG companies, local manufacturers and brand custodians. All types of FMCG products are packed or handled, such as canned food, alcohol, tea and coffee, dairy and frozen foods, sauces and condiments, and bottled water. Its subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Multipack-LJM Pty Ltd, LJM (NSW) Pty Ltd and HH Packaging Pty Ltd.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Probiotec Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.9 AUD

Average target price

3 AUD

Spread / Average Target

+3.45%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROBIOTEC LIMITED	0.00%	159M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.63%	364B
MERCK & CO., INC.	+20.67%	326B
ABBVIE INC.	+5.83%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+11.19%	167B
PFIZER, INC.	+0.05%	161B

Other Pharmaceuticals